Editas Medicine (EDIT) is Upgraded by Jefferies to Buy

Editas Medicine (EDIT) was Upgraded by Jefferies to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Jefferies advised their investors in a research report released on Aug 10, 2016.

Many Wall Street Analysts have commented on Editas Medicine. Editas Medicine was Initiated by Jefferies to “Hold” on Jun 2, 2016.

On the company’s financial health, Editas Medicine reported $-0.80 EPS for the quarter, missing the analyst consensus estimate by $ -0.48 based on the information available during the earnings call on May 16, 2016. Analyst had a consensus of $-0.32. The company had revenue of $.80 million for the quarter, compared to analysts expectations of $1.08 million.

Editas Medicine

Leave a Reply

Editas Medicine - Is it time to Sell?

Top Brokerage Firms are advising their investors on Editas Medicine. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.